NASDAQ:GHRS GH Research (GHRS) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free GHRS Stock Alerts $10.66 -0.05 (-0.47%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$10.59▼$10.8750-Day Range$5.63▼$11.0952-Week Range$5.05▼$14.64Volume44,423 shsAverage Volume141,689 shsMarket Capitalization$554.64 millionP/E RatioN/ADividend YieldN/APrice Target$39.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get GH Research alerts: Email Address GH Research MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside270.5% Upside$39.50 Price TargetShort InterestBearish4.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.96) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.98 out of 5 starsMedical Sector726th out of 938 stocksPharmaceutical Preparations Industry327th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingGH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $39.50, GH Research has a forecasted upside of 270.5% from its current price of $10.66.Amount of Analyst CoverageGH Research has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.47% of the float of GH Research has been sold short.Short Interest Ratio / Days to CoverGH Research has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in GH Research has recently increased by 2.34%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGH Research does not currently pay a dividend.Dividend GrowthGH Research does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GHRS. Previous Next 2.9 News and Social Media Coverage News SentimentGH Research has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for GH Research this week, compared to 1 article on an average week.Search Interest3 people have searched for GHRS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added GH Research to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GH Research insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for GH Research are expected to decrease in the coming year, from ($0.96) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GH Research is -15.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GH Research is -15.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGH Research has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. About GH Research Stock (NASDAQ:GHRS)GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an intravenous mebufotenin product candidate; and GH003, an intranasal mebufotenin product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.Read More GHRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GHRS Stock News HeadlinesMarch 17, 2024 | yahoo.comGeneral Hospital Video Preview: Misdirections, Maladies, and MisdiagnosesMarch 15, 2024 | yahoo.comGeneral Hospital Video Preview: Catastrophic Thoughts Plague Jason and SonnyMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 15, 2024 | yahoo.comThe General Hospital Coming Out Storyline Nobody Saw ComingMarch 4, 2024 | markets.businessinsider.comBuy Rating for GH Research: Promising Clinical Trials and Strategic Intellectual Property AdvancesMarch 1, 2024 | markets.businessinsider.comBuy Rating Justified by GH Research’s Promising Clinical Trials and Strong Financial HealthMarch 1, 2024 | msn.comGH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business UpdatesFebruary 29, 2024 | globenewswire.comGH Research Reports Full Year 2023 Financial Results and Provides Business UpdatesMarch 28, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:January 18, 2024 | finance.yahoo.comGH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant DepressionJanuary 16, 2024 | finance.yahoo.comCan GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?January 16, 2024 | yahoo.comGeneral Hospital Season 61: How Many Episodes & When Do New Episodes Come Out?December 26, 2023 | yahoo.comGeneral Hospital Season 61 Streaming: Watch & Stream Online via HuluDecember 25, 2023 | finance.yahoo.comWe're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash WiselyDecember 20, 2023 | nasdaq.comThese Four Stocks Tap into the Exploding Psychedelic Treatment MarketNovember 24, 2023 | msn.comPsyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And MoreNovember 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: Inuvo (INUV) and GH Research (GHRS)November 10, 2023 | markets.businessinsider.comGH Research Earns ‘Buy’ Rating: Promising Progress, Proactive Approach, and Solid Financial StandingNovember 10, 2023 | finanznachrichten.deGH Research PLC: GH Research Reports Third Quarter Financial Results and Provides Business UpdatesNovember 9, 2023 | finance.yahoo.comGH Research Reports Third Quarter Financial Results and Provides Business UpdatesNovember 2, 2023 | morningstar.comGH Research PLC GHRSOctober 3, 2023 | markets.businessinsider.comPositive Outlook for GH Research Despite FDA’s Clinical Hold: An Analysis of GH001’s Trials and ProspectsOctober 2, 2023 | benzinga.comGH Research's Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On HoldSeptember 30, 2023 | finanznachrichten.deGH Research PLC: GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant DepressionSeptember 29, 2023 | finance.yahoo.comGH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant DepressionAugust 24, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for GH Research (GHRS)August 24, 2023 | markets.businessinsider.comGH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026See More Headlines Receive GHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GHRS CUSIPN/A CIK1855129 Webwww.ghres.com Phone212-450-4000FaxN/AEmployees32Year FoundedN/APrice Target and Rating Average Stock Price Target$39.50 High Stock Price Target$40.00 Low Stock Price Target$39.00 Potential Upside/Downside+270.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-15.48% Return on Assets-15.01% Debt Debt-to-Equity RatioN/A Current Ratio24.49 Quick Ratio24.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book2.16Miscellaneous Outstanding Shares52,030,000Free Float30,384,000Market Cap$554.64 million OptionableOptionable Beta0.79 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Florian Schonharting M.Sc. (Econ) (Age 55)Co-Founder & Non-Executive Chairman of the Board Dr. Theis Terwey M.D. (Age 48)Co-Founder & CEO Mr. Magnus Halle (Age 27)Co-Founder & MD of Ireland Ms. Julie Ryan F.C.A. (Age 38)Vice President of Finance Mr. Aaron Cameron M.B.A. (Age 38)Chief Operating Officer Mr. Naoise GaffneyVP & Head of Intellectual PropertyMore ExecutivesKey CompetitorsCOMPASS PathwaysNASDAQ:CMPSTravere TherapeuticsNASDAQ:TVTXAnaptysBioNASDAQ:ANABArriVent BioPharmaNASDAQ:AVBPFulcrum TherapeuticsNASDAQ:FULCView All CompetitorsInstitutional OwnershipBVF Inc. ILBought 1,125,000 shares on 2/15/2024Ownership: 20.586%Citadel Advisors LLCSold 70,687 shares on 2/15/2024Ownership: 0.192%Barclays PLCSold 32,090 shares on 2/15/2024Ownership: 0.062%Verition Fund Management LLCSold 22,753 shares on 2/14/2024Ownership: 0.000%AdvisorShares Investments LLCBought 1,977 shares on 2/14/2024Ownership: 0.000%View All Institutional Transactions GHRS Stock Analysis - Frequently Asked Questions Should I buy or sell GH Research stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GH Research in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GHRS shares. View GHRS analyst ratings or view top-rated stocks. What is GH Research's stock price target for 2024? 2 brokerages have issued twelve-month price objectives for GH Research's shares. Their GHRS share price targets range from $39.00 to $40.00. On average, they expect the company's stock price to reach $39.50 in the next twelve months. This suggests a possible upside of 270.5% from the stock's current price. View analysts price targets for GHRS or view top-rated stocks among Wall Street analysts. How have GHRS shares performed in 2024? GH Research's stock was trading at $5.80 at the start of the year. Since then, GHRS stock has increased by 83.8% and is now trading at $10.66. View the best growth stocks for 2024 here. When is GH Research's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GHRS earnings forecast. How were GH Research's earnings last quarter? GH Research PLC (NASDAQ:GHRS) released its quarterly earnings results on Thursday, February, 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01. What ETFs hold GH Research's stock? ETFs with the largest weight of GH Research (NASDAQ:GHRS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL).iShares MSCI Ireland ETF (EIRL). When did GH Research IPO? GH Research (GHRS) raised $150 million in an IPO on Friday, June 25th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. Who are GH Research's major shareholders? GH Research's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (20.59%), Verition Fund Management LLC (0.00%), Mirae Asset Global Investments Co. Ltd. (0.00%), Citadel Advisors LLC (0.19%), AdvisorShares Investments LLC (0.00%) and Barclays PLC (0.06%). How do I buy shares of GH Research? Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GHRS) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyInvestors Alert: The Next Big Thing in Weight LossBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.